<DOC>
	<DOCNO>NCT02522104</DOCNO>
	<brief_summary>The use hydroxyurea sickle cell disease patient glomerular hyperfiltration renal failure require specific monitor dose adjustment order remain within therapeutic interval limit risk toxicity therapeutic failure . For reason investigator propose compare pharmacokinetic parameter hydroxyurea normal-renal function sickle cell patient patient glomerular hyperfiltration moderate renal failure .</brief_summary>
	<brief_title>Evaluation Impact Renal Function Pharmacokinetics SIKLOS ® ( DARH )</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Age ≥ 18 year . Male female . Sickle cell disease ( SS Sβ0thal ) confirm haemoglobin electrophoresis genotyping deoxyribonucleic acid ( DNA ) analysis . Affiliation social security system . Having freely consent writing inform objective , programme potential risk incur . These criterion apply 3 group sickle cell disease patient accord renal function stage define glomerular filtration rate ( GFR ) estimate formula Chronic Kidney Disease EPIdemiology ( CKD EPI ) collaboration without ethnic criterion last 6 month inclusion : Normalrenal function : 90 ≤ GFR ≤ 130 mL/min/1.73m2 woman 140 mL/min/1.73m2 men . Moderate renal failure : 30 ≤ GFR ≤ 60 mL/min/1.73m2 . Glomerular renal hyperfiltration : GFR &gt; 130 mL/min/1.73m2 woman GFR &gt; 140 mL/min/1.73m2 men . Treated hydroxyurea ( Siklos® ) stable dosage least one week ± 2 day inclusion study dose administer morning 9:00 ± 15 minute . Refusal consent . Patients comply . Occurrence vasoocclusive crisis month prior inclusion study . Patients exchange transfusion 15 day inclusion study . Patients participate another clinical trial exclusion period previous clinical trial . Patients treat diuretic . Dialysis patient . Patients intercurrent disorder , especially inflammatory , recover least one month . Pregnant breastfeed woman . Patients deprive liberty legal protection . Patients understand objective course study , incapable give consent . In event severe hepatic failure . In event severe renal failure ( creatinine clearance &lt; 30 ml/min ) . Patients show toxic sign bone marrow suppression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pharmacokinetics Hydroxyurea</keyword>
</DOC>